Document:

EX-4.5

 Exhibit 4.5 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

			
	CONFIDENTIAL	  	Execution Copy

 AMENDMENT TO THE DEVELOPMENT COLLABORATION 

AND LICENSE AGREEMENT 

This AMENDMENT (the “Amendment”) entered into on 12 July 2018 (the “Effective Date”) is an amendment to
the DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT dated 27th day of May, 2016, by and between NESTEC S.A., with a place of business at Avenue Nestlé 55, 1800 Vevey, Switzerland
(“NESTEC”) and DBV TECHNOLOGIES, S.A., with a place of business at 177-181 avenue Pierre Brossolette 92120 Montrouge France (“DBV”) (the “Agreement”). NESTEC and DBV
may each be referred to herein individually as a “Party” and collectively as the “Parties.” 
 Capitalized
terms that are used bur not defined in this Amendment shall have the meaning ascribed to this term in the Agreement. 
 RECITALS 

WHEREAS, the collaboration between DBV and NESTEC has progressed and the Parties have agreed to adjustments, as follows based on the
revised Work Plan agreed between the Parties. 
 AGREEMENT 
  

	 	1.	 Changes to Clause 8.2.1. 

The Parties agree that section 8.2.1. shall hereby be replaced in its entirety by the following provisions: 

Development Milestones. NESTEC shall pay to DBV the following non-creditable, non-refundable payment for the first achievement of the following milestone events for the Licensed Product (each, a “Development Milestone”): 

 

			
	 Development Milestone Event / Target Date
	  	Payment
	 1.  [***]
	  	€[***]
	 2.  [***]
	  	€[***]
	 3.  [***]
	  	€[***]
	 4.  [***]
	  	€[***]
	 5.  [***]
	  	€[***]
	 6.  [***]
	  	€[***]

 [***] = CONFIDENTIAL TREATMENT REQUESTED 

 

			
	CONFIDENTIAL	  	Execution Copy

  

			
	 Development Milestone Event / Target Date
	  	Payment
	 7.  [***]
	  	€[***]
	 8.  [***]
	  	€[***]
	 9.  [***]
	  	€[***]
	 10. [***]
	  	€[***]
	 TOTAL Amount of Development Milestones Payments:
	  	€[***]

 The Parties acknowledge that the milestones set forth in (1) and (2) have been achieved as of the Effective Date and that
the corresponding amounts have been duly paid by NESTEC to DBV as of the Effective Date. 
 Further to the milestones set forth in (1) to (10) above,
NESTEC agrees to pay further development milestones of up to €[***]. 
 If any of the milestones set forth in (6), (7) or (8) is achieved whereas
any of the milestones set forth in (3) to (6) has not been achieved, then the applicable milestones set forth in (3), (4) (5) and (6) shall become payable upon achievement of the milestone set forth in (6), ( 7) or (8). If the milestone
set forth in (5) is achieved whereas any of the milestones set forth in (3) or (4) has not been achieved, then the applicable milestones set forth in (3) and (4) shall become payable upon achievement of the milestone set forth in (5).

 Each milestone payment set forth in this Section 8.2.1 shall be payable by NESTEC within [***] after the first achievement of
the applicable Development Milestone for the Licensed Product. If requested by NESTEC, DBV will provide NESTEC with a corresponding invoice for each Development Milestone payment due. 

[***]. 
  

	 	2.	 Miscellaneous 

2.1 Entire Agreement. This Amendment amends and supersedes any conflicting provisions of the Agreement, and forms an entire part of the Agreement.
Together with the Agreement, it constitutes the entire agreement between the Parties and shall cancel and supersede any and all prior and contemporaneous negotiations, correspondence, understandings and agreements, whether oral or written, between
the Parties respecting the subject matter hereof. 
 2.2 Counterparts. This Amendment may be executed in more than one counterpart (including by
electronic transmission), each of which shall be deemed an original, but all of such counterparts taken together shall constitute one and the same agreement. 

  
 Page 2 

			
	CONFIDENTIAL	  	Execution Copy

  

 2.3 Governing Law. Any dispute, claim or controversy arising under or related to this Amendment,
including the construction, validity and performance of this Agreement, shall be governed in all respects by the substantive laws of France.  

[Signature page follows.] 

  
 Page 3 

			
	CONFIDENTIAL	  	Execution Copy

  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized
representatives as of the Effective Date. 
  

					
	For DBV TECHNOLOGIES	 		 	For NESTEC S.A.
			
	/s/ Pierre-Henri Benhamou	 		 	/s/ Claudio Kuoni
			
	By:   Dr Pierre-Henri BENHAMOU	 		 	By:   Claudio Kuoni
	         Chairman and CEO	 		 	General Counsel Nestlé Health Science

  
 Page 4EX-4.17

 Exhibit 4.17 

DBV TECHNOLOGIES S.A. 

NONQUALIFIED STOCK OPTION GRANT NOTICE 

(2018 OPTIONS) 
 The Combined Annual
General Meeting of Shareholders of DBV Technologies (the “Company”) of June 22, 2018 (the “Annual General Meeting”) authorized the Company’s Board of Directors (the
“Board”) to grant options giving entitlement to shares of the Company to the persons that it may name from among the members of staff and officers of the Company and of companies associated with it subject to the terms of
Article L.225-180 of the French Commercial Code. 
 Pursuant to (i) this authorization, the Board decided at
its meeting of June 22, 2018, the policy for allocation of Stock options to employees and Corporate Officers of the subsidiaries outside France according to their grade and the main characteristics of an options plan conferring the entitlement
to subscribe to shares of the Company, known as “DBV Technologies S.A. Stock Option Agreement”. The Board delegated all power to the Chairman & CEO and to the Deputy CEO for the purpose of implementing this policy including
the certification of the allocation decision upon the 15th of the month following the effective date of employment or an employment contract, the purchase price for options and the numbers of
shares allocated to each Optionee. 
 Pursuant to (i) this delegation, the CEO hereby grants to the Optionee named below an option (the
“Stock Option”) to purchase/subscribe on or prior to the Expiration Date specified below all or part of the number of shares of the Company’s Ordinary Shares, €0.10 nominal value per share (each, a
“Share”), specified below at the Option Exercise Price per Share specified below subject to the terms and conditions set forth herein, in the attached Stock Option Agreement and Plan (the “Agreement and
Plan”), all of which are incorporated herein in their entirety. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended, with respect to
Optionees who are US tax residents.  
  

					
	 Name of Optionee:
	 	                                   
                                         
    	 	(the “Optionee”)
	 No. of Options:
	 	                                   
                                         
    	 	
	 No. of Shares:
	 	                                   
                                         
    	 	
	 Grant Date:
	 	                                   
                                         
    	 	1 
	 Expiration Date:
	 	                                   
                                         
    	 	(the “Expiration Date”)2
	 Option Exercise Price/Share:
	 	€                                    
                                         
   	 	(the “Option Exercise Price”)3

  

	1 	 Grant Date will generally be the 15th day of the month following the employee’s hire date (i.e. if
effective date before the 15th, it will be the 15th of the current month; if the effective date after the 15th, it will be the 15th of the following month). if the 15th is not a business day, the Grant date will be the first following business day.

	2 	 Insert date that is 10 years from Grant Date. 

	3 	 Shall equal the closing price of the share on the Euronext Paris on the day that the Grant is recorded, but
will not be less than the average of the share prices quoted over the 20 trading days preceding the date of said grant. 

  
 1 

			
	Vesting Schedule:	 	25 percent of the Shares subject to this Stock Option shall vest on the first anniversary of the Grant Date, subject to the Optionee’s Continuous Service through such date. Thereafter, the remaining 75 percent of the
Shares shall vest in six substantially equal bi-annual installments following the first anniversary of the Grant Date, subject to the Optionee’s Continuous Service through each such date, as set forth in
the Agreement and Plan.

 Exercise conditions: the exercise of this Stock Option is subject to (i) the existence of Continuous Service at the date
of exercise of the said Stock Option in accordance with this Agreement and Plan (and subject to any exception set forth in the Plan) and (ii) the Company having obtained the marketing approval from US Food and Drug Administration (U.S. FDA) of
Viaskin Peanut. 
 Additional Terms/Acknowledgements: Optionee acknowledges receipt of, and understands and agrees to, this Grant Notice (as defined
in this Agreement and Plan), this Agreement and Plan. Optionee acknowledges and agrees that this Grant Notice and this Agreement and Plan may not be modified, amended or revised except as provided herein. Optionee further acknowledges that as
of the Date of Grant, this Grant Notice and this Agreement and Plan set forth the entire understanding between Optionee and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations
on that subject with the exception of (i) options previously granted and delivered to Optionee or (ii) any written employment or severance arrangement that would provide for vesting acceleration of this option upon the terms and conditions
set forth therein. 
 This Grant Notice is not to be interpreted as a guarantee or contract of Continuous Service (as defined in this Agreement and
Plan). 
 By accepting this option, Optionee consents to receive such documents by electronic delivery and to participate in this Agreement and Plan through
an online or electronic system established and maintained by the Company or another third party designated by the Company. 
  

									
	DBV TECHNOLOGIES, S.A.	 		 	OPTIONEE:
				
	By:	 	 	 		 	 
		 	Signature	 		 		 	Signature
	Title:	 	 	 		 	Date:	 	 
	 Date:
	 	 	 		 		 	

  
 2 

 DBV TECHNOLOGIES S.A. 

STOCK OPTION AGREEMENT AND PLAN 

Pursuant to the Stock Option grant notice (the “Grant Notice”) and this Stock Option agreement (this
“Agreement and Plan”), DBV Technologies (the “Company”) has granted Optionee an option (the “Stock Option”) under this Agreement and Plan referenced in the Grant Notice to
purchase/subscribe the number of shares of the Company’s Ordinary Shares, €0.10 nominal value per share (each, a “Share”) indicated in the Grant Notice at the exercise price indicated in the Grant Notice. The Stock
Option is granted to the Optionee effective as of the date of grant set forth in the Grant Notice (the “Grant Date”). Capitalized terms in this Agreement shall have the meaning specified in the Grant Notice unless a different
meaning is specified herein. 
 The details of the Stock Option and this Agreement and Plan generally, in addition to those set forth in the
Grant Notice, are as follows: 
 1. Legal Framework. 

(a) The Combined Annual General Meeting of Shareholders of the Company of June 22, 2018 (the “Annual General
Meeting”) authorized the Board to grant options to purchase and/or subscribe Shares to the persons that it may name from time-to-time among the members of
staff and officers of the Company and of companies associated with it subject to the terms of Article L.225-180 of the French Commercial Code (the “French Code”). This authorization was
given for a period of 18 months from the Annual General Meeting, under the provisions of Articles L.225-177 et seq. of the French Code. 

(b) This Agreement and Plan and this Stock Option shall be administered by the Board. The Board may change the details of this Agreement and
Plan and this Stock Option (including the Grant Notice) (i) if it considers that the change is appropriate and has no significant negative impact on the interests of the Optionees or (ii) with the agreement of the Optionees concerned. More
generally, in case of a change in the legislation, regulations or accounting standards, or a change in the interpretation of such provision, particularly relating to the tax or social security arrangements for the allocation or exercise of options,
the terms and conditions for the options under this Agreement and Plan, including this Stock Option, may be amended by the Board at its discretion, to respond to this change as it sees fit. By way of example, the Board might decide to shorten or
extend the exercise period, or to introduce a mandatory retention period. 
 (c) The Board will have the power, subject to, and within the
limitations of, the express provisions of this Agreement and Plan: (i) to construe and interpret this Agreement and Plan and this Stock Option (including the Grant Notice) and (ii) to settle all controversies regarding this Agreement and
Plan and awards granted under it, including this Stock Option. 
 (d) The Board may delegate some or all of the administration of this
Agreement and Plan to the Company’s Chief Executive Officer, provided such delegation complies with French law. The Board may retain the authority to concurrently administer this Agreement and Plan with the Chief Executive Officer and may, at
any time, revest in the Board some or all of the powers previously delegated. 

 (e) All determinations, interpretations and constructions made by the Board in good faith
will not be subject to review by any person and will be final, binding and conclusive on all persons. 
 2. Vesting. Subject to the
provisions contained herein, the Stock Option will vest as provided in the Grant Notice and as set forth below during a planned vesting period of four (4) years: 
  

	 	•	 	 0% of the total number of Stock Options granted to the Optionee shall vest between the Grant Date and the first
anniversary date of the Grant Date (excluded); 

  

	 	•	 	 25% of the total number of Stock Options granted to the Optionee shall vest as from the first anniversary date of
the Grant Date (included); 

  

	 	•	 	 an additional 12.5 % of the total number of Stock Options granted to the Optionee shall vest after
eighteen (18) months as from the Grant Date; 

  

	 	•	 	 an additional 12.5 % of the total number of Stock Options granted to the Optionee shall vest after
twenty-four (24) months as from the Grant Date; 

  

	 	•	 	 an additional 12.5 % of the total number of Stock Options granted to the Optionee shall vest after
thirty (30) months as from the Grant Date; 

  

	 	•	 	 an additional 12.5 % of the total number of Stock Options granted to the Optionee shall vest after thirty-six (36) months as from the Grant Date; 

  

	 	•	 	 an additional 12.5 % of the total number of Stock Options granted to the Optionee shall vest after forty-two (42) months as from the Grant Date; and 

  

	 	•	 	 an additional 12.5 % of the total number of Stock Options granted to the Optionee shall vest after
forty-eight (48) months as from the Grant Date. 

 Vesting will cease upon the termination of Optionee’s Continuous Service,
unless otherwise provided below. Upon a Takeover, the Stock Options will be deemed 100% vested and exercisable. 
 The Stock Options are exercisable within
a ten (10) year period as from the Grant Date and in accordance with the provisions of this Agreement and Plan. 
 3. Number of
Shares and Exercise Price. The number of Shares subject to this Stock Option and the Option Exercise Price are set forth in the Grant Notice. As provided for in the Grant Notice, each Stock Option shall give entitlement to acquire/subscribe to
one (1) Share, subject to adjustments provided for in Section 10 below. 

  
 - 4 - 

 For the avoidance of doubt, it is specified that the Option Exercise Price shall correspond
to the price of the Shares on Euronext Paris on the Grant Date, but will not be less than the average of the share prices quoted over the twenty (20) trading days preceding the Grant Date. 

4. Manner of Exercise. 

(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this
Stock Option and in accordance with the terms of this Stock Options, the Optionee may give written notice to the Company of his or her election to purchase/subscribe some or all of the Shares subject to this Stock Option purchasable/being available
to subscription at the time of such notice. This notice shall specify the number of Shares to be purchased/subscribed. 
 (b) Payment of the
purchase price for the Shares may be made in cash, by certified or bank check or other instrument acceptable to the Board or, if allowable under applicable law, by way of offsetting receivables held by the Optionee against the Company. 

(c) Payment instruments will be received subject to collection. The transfer to the Optionee on the records of the Company or of the transfer
agent of the Shares will be contingent upon (i) the Company’s receipt from the Optionee of the full purchase/subscription price for the Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in
this Agreement and Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Shares to be
purchased/subscribed pursuant to the exercise of Stock Options under this Agreement and Plan and any subsequent resale of the Shares will be in compliance with applicable laws and regulations. 

(d) The Shares purchased/subscribed upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or
of the transfer agent upon compliance to the satisfaction of the Board with all requirements under this Agreement and Plan, applicable laws or regulations in connection with such transfer and with the requirements hereof. The determination of the
Board as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any Shares subject to this Stock Option unless and until this
Stock Option shall have been exercised pursuant to the terms hereof, the Company shall have transferred the shares to the Optionee, and the Optionee’s name shall have been entered as the stockholder of record on the books of the Company.
Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such Shares. Such Shares shall be freely transferable once the Stock Option has been exercised, subject to compliance with the applicable legal and
regulatory provisions as set forth in Sections 7 and 13 below. 
 (e) Notwithstanding any other provision hereof or of this Agreement and
Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof, unless allowable under applicable law. 

  
 - 5 - 

 5. Exercise Conditions. The exercise of this Stock Option is subject to: 

(a) the existence of Continuous Service at the date of exercise of the said Stock Option in accordance with this Agreement and Plan (and
notably Section 6 below), and 
 (b) the Company having obtained the marketing approval from US Food and Drug Administration (U.S. FDA)
of Viaskin Peanut. This condition shall be determined by the Board of Directors (the Performance Condition). 
 6. Termination of
Continuous Service. The exercise of the Stock Option is subject to the existence of Continuous Service at the date of exercise of the said Stock Option in accordance with this Agreement and Plan, subject to the exceptions set forth in this
Section 6. If the Optionee’s Continuous Service is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below. 

(a) Termination Due to Death. If the Optionee’s Continuous Service terminates by reason of the Optionee’s death, any portion
of this Stock Option shall be fully vested, and may thereafter be exercised (subject to completion of the Performance Condition at the date of exercise) by the Optionee’s heir(s) for a period of six (6) months from the date of death, even
if such date falls after the Expiration Date. 
 (b) Termination Due to Disability. If the Optionee’s Continuous Service
terminates by reason of the Optionee’s Disability, any portion of this Stock Option outstanding on such date according to the vesting schedule set forth in Section 2 may thereafter be exercised by the Optionee (subject to completion
of the Performance Condition at the date of exercise) for a period of six months from the date of Disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not vested on the date of Disability shall terminate
immediately and be of no further force or effect. 
 (c) Termination for Cause. If the Optionee’s Continuous Service terminates
for Cause, any portion of this Stock Option outstanding on such termination date according to the vesting schedule set forth in Section 2, to the extent exercisable on such termination date, shall terminate immediately and be of no further
force and effect. Any portion of this Stock Option that is not vested on such termination date shall also terminate immediately and be of no further force and effect. 

(d) Retirement. If the Optionee’s Continuous Service terminates as a result of Retirement, any portion of this Stock Option
outstanding on such date according to the vesting schedule set forth in Section 2 may thereafter be exercised (subject to completion of the Performance Condition) by the Optionee at any time before the Expiration Date of the Stock Option.
Any portion of this Stock Option that is not vested on the date of Retirement shall continue to vest in accordance with the vesting schedule set forth in Section 2 and become exercisable after attainment of vesting (subject to completion of the
Performance Condition) at any time before the Expiration Date of the Stock Option. 

  
 - 6 - 

 (e) Other Termination. If the Optionee’s Continuous Service terminates for any
reason (including a termination further to a Takeover) other than the Optionee’s death, the Optionee’s Disability, the Optionee’s Termination for Cause or the Optionee’s Retirement, any portion of this Stock Option outstanding on
such date according to the vesting schedule set forth in Section 2 may be exercised, to the extent exercisable on the date of termination (subject to completion of the Performance Condition), for a period of (i) ninety (90) days from
the date of termination if the Optionee is a U.S. employee of a Group Company or (ii) six (6) months from the date of termination for Optionee other than U.S. employee of a Group Company, or until the Expiration Date, if earlier. Any portion of
this Stock Option that is not vested on the date of termination shall terminate immediately and be of no further force or effect. 
 For the avoidance of
doubt, the date of termination of the Optionee’s Continuous Service shall be as follows, it being specified that such date of termination may be adapted from time to time depending on any local applicable laws: 

 

	 	•	 	 in the event of death or Disability, the date of such Optionee’s death or determination of Disability;

  

	 	•	 	 in the event of resignation of the contract of employment or the corporate mandate, with effect from the day that
the Group Company receives the letter of resignation from the Optionee or the day that it is handed to an authorized representative of the Group Company; 

  

	 	•	 	 in the event of dismissal, with effect from the day that the relevant party receives the dismissal notification
letter, notwithstanding (i) a notice period, whether or not completed; (ii) any challenge by the Optionee to their dismissal and/or the reasons for it; and (iii) any legal ruling that would challenge the grounds for the dismissal;

  

	 	•	 	 in the event of contractual termination, with effect from the administrative approval of the termination
agreement; 

  

	 	•	 	 in the event of the revocation of the corporate mandate, with effect from the day of the meeting of the executive
body deciding on its revocation if the Optionee is in attendance, or, if he is not in attendance, from the date that notification of this decision is received, notwithstanding (i) a notice period, whether or not completed; (ii) any
challenge by the Optionee to the revocation and/or the reasons for it; and (iii) any legal decision that would challenge the validity of the revocation; 

  

	 	•	 	 in the event of the non-renewal of the corporate mandate, with effect
from the expiry date of the corporate mandate. 

 If the Optionee is a U.S. employee of a Group Company, the date of termination shall be
as follows: 
  

	 	•	 	 in the event of death or Disability, the date of such Optionee’s death or determination of Disability by the
Company Group or its designee; 

  

	 	•	 	 in the event of resignation (or equivalent) by the Optionee, the date specified in any letter of resignation by
the Optionee or such as earlier date as determined in its sole discretion by the Group Company in which the Optionee holds an employee or Director position at the date of termination; 

  
 - 7 - 

	 	•	 	 in the event of termination (dismissal, removal or equivalent) of the Optionee’s Continuous Service by the
Group Company in which the Optionee holds an employee or Director position, the date specified by such Group Company; 

  

	 	•	 	 in the event that there is a contract of employment or a corporate mandate bewteen the Optionee and the Group
Company in which the Optionee holds an employee or Director position, the date specified in such contract of employment or contract mandate for the relevant type of termination or as mutually agreed by the parties; or 

 

	 	•	 	 in the event of agreed termination (or equivalent), the date of execution of the termination agreement by all
parties. 

 The Board’s determination of the reason for termination of the Optionee’s Continuous Service shall
be conclusive and binding on the Optionee and his or her legal heirs. 
 7. Suspension of Exercise Rights. 

(a) Notwithstanding anything in this Agreement and Plan, this Stock Option may not be exercised (i) for a period of 30 calendar days
prior to the publication of the annual and half-yearly results, (ii) for a period of 15 calendar days prior to the publication of the quarterly revenue figures or (iii) when Optionee holds “inside information.” For this purpose,
“inside information” is any information which, if made public, could have a significant influence on the price determined in accordance with 7.1 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of
16 April 2014 on market abuse. 
 (b) In addition, the Board may also elect to temporarily suspend the right to exercise this Stock
Option, upon occurence of certain financial transactions involving the share capital of the Company and which require accurate prior knowledge of the number of issued shares composing the share capital of the Company. In such event, Optionee will be
informed by letter of the date on which exercise is suspended and the date of resumption. This information shall be provided by non-recorded delivery, with seven days’ advance notice. 

(c) If the event the Optionee’s Continuous Service terminates during any exercise suspension period, Optionee may exercise this Stock
Option at the end of the suspension period (to the extent then exercisable and subject to completion of the Performance Condition) for an additional period that is equal to the term of the suspension (or if earlier, through the Expiration Date),
without this period extending the initial term of validity of the Stock Option. 
 8. Transferability. This Stock Option is not
transferable and non-assignable as provided for in Article L.225-183 of the French Code, subject to the provisions of Section 6 (a) above. 

9. Tax Withholding Obligations. 

(a) At the time this Stock Option is exercised, in whole or in part, and at any time thereafter as requested by the Company, Optionee hereby
authorizes withholding from payroll and any other amounts payable to Optionee, and otherwise agrees to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or a
Subsidiary, if any, which arise in connection with the exercise of this Stock Option. 

  
 - 8 - 

 (b) Optionee may not exercise this Stock Option unless the tax withholding obligations of
the Company and/or any Subsidiary are satisfied. Accordingly, Optionee may not be able to exercise this Stock Option when desired even though the option is vested, and the Company will have no obligation to issue a certificate for such Shares or
otherwise enter Optionee’s name as the stockholder of record on the books of the Company, unless such obligations are satisfied. 
 (c)
Optionee hereby agrees that the Company does not have a duty to design or administer this Agreement and Plan or its other compensation programs in a manner that minimizes Optionee’s tax liabilities. Optionee will not make any claim against the
Company, or any of its officers, directors, employees, Subsidiaries or affiliates related to tax liabilities arising from this Stock Option or Optionee’s other compensation and the Company encourages the Optionee to consult at his/her own
expenses with his/her own tax adviser to determine the tax consequences applicable to him/her in relation to this Stock Option. In particular, in the event the Optionee is a US tax resident, Optionee acknowledges that this option is exempt from
Section 409A of the Code only if the exercise price per share is at least equal to the “fair market value” per Share on the Grant Date and there is no other impermissible deferral of compensation associated with the option. 

 10. Adjustments for Changes in Capitalization. In the case of an event described in Article
L.225-181 of the French Code, the Company shall take the necessary action to protect the interests of the Optionee beneficiaries under the conditions stipulated in Article
L.228-99 of the French Code. For this purpose, the Company will take all the measures stipulated in Article L.228-99 of the French Code. In particular, it may adjust the
number of Shares subject to this Stock Option and the Option Exercise Price under the conditions and following the procedures laid down by the regulatory provisions of the French Code for each scenario that qualifies for an adjustment. The
Board’s adjustments shall be final, binding and conclusive. 
 11. No Obligation to Continue Service. Neither the Company nor
any Subsidiary is obligated by or as a result of this Agreement and Plan to continue the Optionee’s Continuous Service and this Agreement and Plan shall not interfere in any way with the right of the Company or any subsidiary to terminate the
employment or other service of the Optionee at any time or for any reason. 
 12. Data Privacy. In order to administer this Agreement
and Plan and to implement or structure future equity grants, the Company, its Subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data,
including but not limited to any identification number (excluding the social security number), home address and telephone number, date of birth and other information that is necessary or desirable for the administration of this Agreement and (the
“Relevant Information”). By entering into this Agreement and Plan, the Optionee acknowledges being informed (i) of the legitimate interest of the Company to collect, process, register and disclose to the Relevant
Companies all Relevant Information; (ii) that the Relevant Companies may store and transmit such information in electronic form; and (iii) that the Relevant Information may be transferred to any jurisdiction in

  
 - 9 - 

 
which the Relevant Companies consider appropriate, being specified that where the concerned jurisdiction is not located within the European Union, the Company undertakes to take all relevant
guarantees, either on the basis of an adequacy decision or, in the absence of such a decision, on the basis of appropriate safeguards (e.g. binding corporate rules or contractual clauses), whose copy can be made available upon request. The Relevant
Information will be stored only for the required duration for the purposes of administering this Agreement and Plan and implementing or structuring future equity grants as well as, beyond, for the purposes of evidence and legal obligations for a
period not exceeding the applicable statutory limitation periods. The Optionee shall have access to, and the right to change, delete, if any limit or object, subject to legitimate and compelling reasons, the Relevant Information. These rights can be
exercised directly by notifying the Company under the conditions stated in Section 17 below. 
 13. Trading Policy Restrictions.

 (a) Exercise of this Stock Option and the disposition of any Shares issued in connection therewith shall be subject to the Company’s
insider trading policies and procedures, and all applicable laws regarding insider trading, restriction on exercise and sale of the Shares as in effect and applicable to Optionee from time to time. In addition, Optionee acknowledges receipt of the
Company’s policy permitting certain individuals to sell shares and exercise options only during certain “window” periods and the Company’s insider trading policy, in effect from time to time. 

(b) In accordance with the provisions of Article L.621-18-2 of
the French Monetary and Financial Code, the exercise of this Stock Option and the disposition of any Shares issued in connection therewith by a corporate officer or any person who has, within the Company, (i) the power to take management
decisions regarding its development and strategy, (ii) regular access to inside information relating directly or indirectly to the Company, requires that the French Autorité des Marchés Financiers be informed, with a copy
sent to the Company, within the timeframe laid down in the regulations currently in force (currently within five (5) trading days). 

14. Claw Back. For US employees, any amounts paid (or shares of Common Stock granted) under this Stock Option will be subject to
recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise
required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for “good reason” or
“constructive termination” (or similar term) under any plan of or agreement with the Company. 
 15. Governing Law. This
Agreement and Plan are subject to and must be interpreted according to the provisions of French law and any dispute relating thereto will fall under the exclusive competence of the court with appellate jurisdiction for the location of the
Company’s registered office. 

  
 - 10 - 

 16. Certain Definitions. 

(a) “Board” means the Board of Directors of the Company, or as context requires, the group then responsible for
administration of this Stock Option and/ this Agreement and Plan at the relevant time (i.e., either the Board or a committee or committees of the Board, as applicable) or delegated relevant administrative authority with respect to this Agreement and
Plan and/or this Stock Option. 
 (b) “Cause” shall mean, unless otherwise provided in an employment agreement
between a Group Company and the Optionee, as determination by the Group Company to dismiss the Optionee as a result of the Optionee’s gross negligence or willful misconduct. Such definition may be adapted from time to time depending on any
local applicable laws defining “cause” in terms comparable to Cause. 
 For the sake of clarity, it is specified that for: 

 

	 	•	 	 U.S. employees, “Cause” shall mean, (i) the Optionee’s dishonest statements or acts with
respect to the Company or any Subsidiary or affiliate of the Company, or any of the Company or any Subsidiary’s current or prospective customers, suppliers vendors or other third parties with which such entity does business; (ii) the
Optionee’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Optionee’s gross negligence or willful misconduct with respect to the Company or any Subsidiary
or affiliate of the Company; or (iv) the Optionee’s material violation of any provision of any agreement(s) between the Optionee and the Company (or any Subsidiary of the Company) relating to noncompetition, nondisclosure and/or assignment
of inventions; 

  

	 	•	 	 French employee, “Cause” shall mean the Optionee’s (i) gross negligence
“faute grave” as this notion is determined by the labor division of the French Cour de cassation or (ii) willful misconduct “faute lourde” as this notion is determined by the labor division of the
French Cour de cassation. 

 (c) “Code” means the U.S. Internal Revenue Code of 1986, as
amended. 
 (d) “Continuous Service” means that the Optionee’s service with a Group Company, whether as an
employee or Director, is not interrupted or terminated. A change in the capacity in which the Optionee renders service to a Group Company as an employee or Director or a change in the entity for which the Optionee renders such service, provided that
there is no interruption or termination of the Optionee’s service with the a Group Company, will not terminate the Optionee’s Continuous Service; provided, however, that if the entity for which the Optionee is rendering
services ceases to qualify as a Group Company, as determined by the Board, in its sole discretion, the Optionee’s Continuous Service will be considered to have terminated on the date such entity ceases to qualify as a Group Company. To the
extent permitted by law, the Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by
the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, a Subsidiary, or their successors. Notwithstanding the foregoing, a leave of absence will be treated
as Continuous Service for purposes of vesting only to such extent as may be provided in the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to

  
 - 11 - 

 
the Optionee, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section 409A of the Code, the determination of whether there has been
a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of “separation from service” as defined under Treasury Regulation
Section 1.409A-1(h) (without regard to any alternative definition thereunder). 
 (e)
“Director” shall mean a member of the Board of Directors of the Company. 
 (f) “Disability” means
the inability of the Optionee to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous
period of not less than 12 months, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. Such definition may be adapted from time to time depending on any local applicable
laws defining “disability” in terms comparable to Disability. 
 For the sake of clarity, it is specified that for (i) U.S.
employees, Disability shall have the meaning ascribed to it in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code or as determined under any applicable company long-term disability plan and (ii) French employees, Disability shall have
the meaning ascribed to it in Article L.341.4 of the French Social Security Code. 
 (g) “Group” means the Company
and its Subsidiaries. 
 (h) “Group Company” means a company of the Group. 

(i) “Retirement” means (i), if the Optionee is a U.S. employee of a Group Company, termination of
Continuous Service after attainment of age 62 or (ii), in respect of Optionee other than U.S. employee of a Group Company, termination of Continuous Service due to retirement as decided by the Optionee or by the Group Company as provided for under
any applicable law. 
 (j) “Subsidiary” means, with respect to the Company, (i) any corporation of which more
than 50 percent of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will
have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has a direct
or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50 percent. 

(k) “Takeover” has the meaning provided in Article L.233-3 of the French Code.
Such definition may be adapted from time to time depending on any local applicable laws defining “takeover” in terms comparable to Takeover. For the avoidance of doubt, it is specified that a Takeover for a U.S. Optionee also complies with
the definition of “change of control” under Section 409A of the Code. 

  
 - 12 - 

 17. Notices. Notices hereunder shall be mailed or delivered to the Company at its
principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing. The Company may, in
its sole discretion, decide to deliver any documents related to participation in this Agreement and Plan and this Stock Option by electronic means or to request the Optionee’s consent to participate in this Agreement and Plan by electronic
means. By accepting this Stock Option, the Optionee consent to receive such documents by electronic delivery and to participate hereunder through an on-line or electronic system established and maintained by
the Company or another third party designated by the Company from time-to-time. 

  
 - 13 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]